- Home
- PFO vs ALDX Comparison
PFO vs ALDX Comparison
Compare PFO & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFO | ALDX |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.5M | 101.1M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | PFO | ALDX |
|---|---|---|
| Price | $9.29 | $1.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 29.2K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.01 | $1.07 |
| 52 Week High | $9.90 | $6.18 |
Technical Indicators
Market Signals| Indicator | PFO | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 52.15 | 34.77 |
| Support Level | $9.16 | $1.48 |
| Resistance Level | $9.29 | $1.89 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 34.48 | 27.38 |
Price Performance
Historical ComparisonAbout PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.